Cardiology (all articles) | Page 64 of 178 | Links Medicus Content Curation & Alerts in Medicine

M-A: Diagnostic features, management and prognosis of type 2 myocardial infarction compared to type 1 myocardial infarction.

22 Feb, 2022 | 08:34h | UTC

Diagnostic features, management and prognosis of type 2 myocardial infarction compared to type 1 myocardial infarction: a systematic review and meta-analysis – BMJ Open

Early and late-onset syncope: insight into mechanisms.

22 Feb, 2022 | 08:29h | UTC

Early and late-onset syncope: insight into mechanisms – European Heart Journal

Commentary on Twitter

Early and late-onset syncope: insight into mechanisms https://t.co/OlAT50jIt8 @escardio #EHJ #ESCYoung #cardiotwitter @ehj_ed @rladeiraslopes pic.twitter.com/F2gzBH9X2i

— European Society of Cardiology Journals (@ESC_Journals) February 17, 2022

Expert Analysis | Asymptomatic ventricular preexcitation (Wolff-Parkinson-White Pattern): when to be concerned.

22 Feb, 2022 | 08:18h | UTC

Asymptomatic Ventricular Preexcitation (Wolff-Parkinson-White Pattern): When to Be Concerned – American College of Cardiology

ESCMID rapid guidelines for assessment and management of long COVID.

21 Feb, 2022 | 09:31h | UTC

ESCMID rapid guidelines for assessment and management of long COVID – Clinical Microbiology and Infection

ERS statement on Long COVID-19 follow-up.

Proposed subtypes of long-Covid and their respective potential therapies.

EuGMS Guidance: Management of post-acute COVID-19 patients in geriatric rehabilitation.

Addressing Post-COVID Symptoms: A Guide for Primary Care Physicians.

Global surveillance, research, and collaboration needed to improve understanding and management of long COVID.

Provocative study suggests that persistent physical symptoms after COVID-19 infection may be associated more with the belief in having been infected with SARS-CoV-2 than with having laboratory-confirmed COVID-19 infection.

Update to post-acute sequelae of SARS-CoV-2 infection: Caring for the ‘long-haulers’.

Systematic Review: Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection.

WHO Consensus: A clinical case definition of post COVID-19 condition (Long Covid).

Characterizing long COVID: a living systematic review.

Long Covid – The illness narratives.

New guidelines to help doctors manage long COVID patients published.

M-A: More than 50 long-term effects of COVID-19. (several articles on the subject)

Review | Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus.

21 Feb, 2022 | 09:30h | UTC

Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus – European Heart Journal

News Release: Review highlights impact of Long COVID on cardiovascular system – University of Oxford

The pathogenesis and long-term consequences of Covid-19 cardiac injury: state-of-the-art review.

COVID-19 infections increase risk of heart conditions up to a year later, study finds.

A clinical update on vasoactive medication in the management of cardiogenic shock.

21 Feb, 2022 | 08:14h | UTC

A Clinical Update on Vasoactive Medication in the Management of Cardiogenic Shock – Clinical Medicine Insights: Cardiology

The pathogenesis and long-term consequences of Covid-19 cardiac injury: state-of-the-art review.

18 Feb, 2022 | 09:56h | UTC

The Pathogenesis and Long-Term Consequences of COVID-19 Cardiac Injury: State-of-the-Art Review – JACC: Basic to Translational Science

Arrhythmias in female patients: incidence, presentation and management.

18 Feb, 2022 | 08:31h | UTC

Arrhythmias in Female Patients: Incidence, Presentation and Management – Circulation Research (free for a limited period)

Review: Cardiac considerations in liver transplantation.

18 Feb, 2022 | 08:26h | UTC

Cardiac considerations in liver transplantation – Cleveland Clinic Journal of Medicine

Meta-analysis finds the overall prevalence of statin intolerance is around 9% and identifies the most common risk factors.

17 Feb, 2022 | 10:07h | UTC

Prevalence of statin intolerance: a meta-analysis – European Heart Journal

Commentaries:

Study shows the true prevalence of statin intolerance worldwide is between 6 to 10% – News Medical / European Society of Cardiology

Expert reaction to study looking at statin intolerance – Science Media Centre

Side effect patterns in a crossover trial of statin, placebo, and no treatment – This N-of-1 trial, now published in full, suggests the nocebo effect causes most of statins muscle adverse effects.

#AHA20 – In patients who had discontinued statins because of side effects, a N-of-1 trial of a statin, placebo, or no treatment found that side effects often attributed to statins were the same for those taking a placebo

Commentary on Twitter

Statin intolerance is “over-estimated and over-diagnosed”. World’s largest study shows less than 10% suffer side-effects caused by statins https://t.co/pcVk8YI3I3 @escardio #EHJ #ESCYoung #cardiotwitter @ehj_ed @rladeiraslopes #CVD #Riskfactors pic.twitter.com/b3nFWsc74d

— European Society of Cardiology Journals (@ESC_Journals) February 16, 2022

Review: Diagnosis and treatment of acute coronary syndromes.

17 Feb, 2022 | 10:04h | UTC

Diagnosis and Treatment of Acute Coronary Syndromes: A Review – JAMA (free for a limited period)

Audio clinical review: Diagnosis and Treatment of Acute Coronary Syndromes – JAMA

Review: Transcatheter treatment for tricuspid valve disease.

16 Feb, 2022 | 08:37h | UTC

Transcatheter treatment for tricuspid valve disease – EuroIntervention

Podcast | Hypertension FAQ: Common Outpatient Cases.

16 Feb, 2022 | 08:36h | UTC

#321 Hypertension FAQ: Common Outpatient Cases with Dr. Jordy Cohen – The Curbsiders

Systematic Review: Electrocardiographic features of left ventricular diastolic dysfunction and heart failure with preserved ejection fraction.

15 Feb, 2022 | 09:47h | UTC

Electrocardiographic Features of Left Ventricular Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: A Systematic Review – Frontiers in Cardiovascular Medicine

M-A: Single antiplatelet therapy should be used after transcatheter aortic valve implantation in patients without indication for anticoagulation.

15 Feb, 2022 | 08:32h | UTC

Comparing Single- and Dual-Antiplatelet Therapies After Transcatheter Aortic Valve Implantation – The Annals of Thoracic Surgery (link to abstract – $ for full-text)

M-A: Aspirin alone better than dual antiplatelet therapy after transcatheter aortic valve implantation

#ESCCongress – [Abstract Only] Randomized trial: aspirin with or without clopidogrel after transcatheter aortic-valve implantation

#ACC21 – [Not published yet] RCT: Among patients undergoing TAVR, full-dose apixaban is not superior to standard of care (vitamin K antagonist if indication for oral anticoagulation; antiplatelet therapy if no indication).

#AHA19 – [Abstract Only] Randomized Trial: An Antiplatelet-based Strategy is Associated with Better Outcomes vs. Anticoagulation After Transcatheter Aortic-Valve Replacement

Futility in Transcatheter Aortic Valve Implantation: A Search for Clarity.

15 Feb, 2022 | 08:26h | UTC

Futility in Transcatheter Aortic Valve Implantation: A Search for Clarity – Interventional Cardiology

WHO Guideline: Hypertension pharmacological treatment in adults.

13 Feb, 2022 | 22:23h | UTC

Hypertension Pharmacological Treatment in Adults: A World Health Organization Guideline Executive Summary – Hypertension

RCT: In patients with cardiogenic shock receiving VA-ECMO, moderate hypothermia did not significantly reduce 30-day mortality. 42% of patients in the moderate hypothermia group died vs. 51% in the normothermia group (adjusted odds ratio, 0.71 [95% CI, 0.45 to 1.13], P = .15).

13 Feb, 2022 | 22:11h | UTC

Effect of Moderate Hypothermia vs Normothermia on 30-Day Mortality in Patients With Cardiogenic Shock Receiving Venoarterial Extracorporeal Membrane Oxygenation: A Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)

Commentary: Hypothermia vs. Normothermia for Cardiogenic Shock Patients on VA-ECMO – American College of Cardiology

Commentary on Twitter

In this RCT, for patients with cardiogenic shock receiving venoarterial ECMO, moderate hypothermia for 24 hours compared with normothermia did not significantly decrease 30-day mortality. https://t.co/0LKYJ1bNB3 pic.twitter.com/KmXPAlvqh9

— JAMA (@JAMA_current) February 2, 2022